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Background: Chronic stable angina (CSA) has a major negative impact on health-related quality of life (HRQL)
including poor general health status, psychological distress, and inability to self-manage.
Methods: We used meta-analysis to assess the effectiveness of self-management interventions for improving stable
angina symptoms, HRQL and psychological well-being. Nine trials, involving 1,282 participants in total, were included.
We used standard inverse-variance random-effects meta-analysis to combine the trials. Heterogeneity between trials
was evaluated using chi-square tests for the tau-squared statistic and quantified using the I2 statistic.
Results: There was significant improvement in the frequency of angina symptoms (Seattle Angina Questionnaire [SAQ],
symptom diary) across trials, standardized mean difference (SMD): 0.30 (95% Confidence interval [CI] 0.14, 0.47), as well
as reduction in the use of sublingual (SL) nitrates, SMD: −0.49 (95% CI −0.77, −0.20). Significant improvements for physical
limitation (SAQ), SMD: 0.38 (95% CI 0.20, 0.55) and depression scores (Hospital Anxiety and Depression Scale), SMD: −1.38
(95% CI −2.46, −0.30) were also found. The impact of SM on anxiety was uncertain due to statistical heterogeneity
across trials for this outcome, I2 = 98%. SM did not improve other HRQL dimensions including angina stability,
disease perception, and treatment satisfaction.
Conclusions: SM interventions significantly improve angina frequency and physical limitation; they also decrease
the use of SL nitrates and improve depression in some cases. Further work is needed to make definitive conclusions
about the impact of SM on cardiac-specific anxiety.
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Chronic stable angina (CSA) is a primary symptom of
coronary artery disease (CAD) characterized by the pre-
dictable occurrence of pain or discomfort in the subster-
nal and adjacent areas of the chest [1]. Symptomatology
can vary in terms of severity (Canadian Cardiovascular
Society [CCS] class) and may include anginal equivalents
such as nausea, breathlessness upon exertion, and/or
fatigue [1]. Classic presentation of CSA is featured by
reversibility of symptoms and repetitiveness of angina
episodes over time, typically months or years [2]. As CAD* Correspondence: mmcgill@mcmaster.ca
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stated.survival rates increase, the global prevalence of CSA
is also rising. Prevalence estimates suggest that CSA
affects 3.8% of Americans aged 20 and over (6 million)
and 1.9% of Canadians over the age of 12 (n = 483,000)
[3]. In Scotland, CSA is prevalent in 2.6% of the general
population, with 28 per 1000 men and 25 per 1000
women being affected, respectively [4].
The public health burden of CSA is considerable.
Cumulative data indicate that those with CSA are
among the most debilitated across several chronic ill-
ness populations including sciatica, arthritis, low back
pain, and stroke [5]. With respect to CAD in particular,
a recent retrospective cohort study (n = 1,609) found that
those with CSA alone were more physically incapacitated
than those with a history of previous myocardial (MI)al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Risk of bias assessment of included trials expressed
as yes/no/unclear.
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from physical limitation, CSA also imposes significant psy-
chological impact on health-related quality of life (HRQL).
Many patients report heart-focused attention and anxiety,
fear of death, depression, impaired role functioning, and
poor sense of general health and well-being [7-9]. This
high level of symptom burden has major financial conse-
quences both at patient and health care system levels. At
the patient level, McGillion et al. estimated the cost of
CSA-related disability— expressed as direct out of pocket,
indirect and system costs— at $19,209 per annum; this
estimate was likely to be conservative due to reliance on
self-report measures [10]. In the UK, the direct system
costs of angina symptom management including prescrip-
tions, hospital admissions, outpatient referrals, and inves-
tigational procedures, were estimated in 2000 at ₤669,
000, 000, accounting for 1.3% of total National Health Ser-
vice expenditure [11].
Increasing attention has being given to angina self-
management [SM] interventions as an adjunctive means
to offset the symptom-related burden of CSA. The goal
of SM is to prevent or slow chronic illness symptom-
related disability and restore functioning and life roles to
optimal levels. Typical SM programs provide educational
materials and coaching methods to achieve positive
changes in knowledge and behaviour for effective disease
self-management. Program models vary but are commonly
grounded in social cognitive and learning theories, such as
Bandura’s Self-Efficacy Theory [12], which targets the fol-
lowing mediators of individual performance: a) perceived
self-efficacy or confidence, and b) perceived effectiveness
of learned behaviours to achieve desired health outcomes.
Published randomized clinical trials (RCTs) of angina SM
programs to date have targeted improvements in angina
symptom profile and related SL nitrate use, functional as-
pects of HRQL, and psychological well-being [13-21]. Our
aim was to examine comprehensively the overall effective-
ness of SM for improving these outcomes.
Criteria for selection of studies included in this
review
Types of studies
We included all published and unpublished RCTs of SM
interventions delivered by a trained professional or lay-
trained facilitator in individual or group formats, with
parallel designs; length of follow up period varied. Non-
randomized studies and single-group design studies were
excluded.
Types of participants
Adult outpatients of all ages with ischemic heart disease
(IHD) and Canadian Cardiovascular Society (CCS) Class
I – IV angina, reporting stable symptoms for at least
3 months, were included.Types of interventions and controls
Interventions employing a combination of cognitive and be-
havioural angina self-management techniques were included
such as: supportive coaching, anxiety and stress management
or counselling, incremental exercise program, nutrition plan-
ning, medication review, relaxation training, and energy con-
servation. Controls received routine or usual care and were
not exposed to the intervention during the study period.
Types of outcome measures
1. Angina symptom profile including angina frequency
and stability and related SL nitrate use
2. HRQL dimensions including physical limitation,
disease perception, and treatment satisfaction
3. Psychological well-being, reflected by anxiety and
depression
Methods
Search for identification of studies
We searched the Cochrane Central Register of Controlled
Trials, MEDLINE, PubMed, CINHAL, EMBASE, Proquest
Dissertation Abstracts, Psychinfo and HealthStar, Jan.
1990 – Aug. 2013, using combinations of key medical
subject heading (MeSH) terms including chronic stable
McGillion et al. BMC Cardiovascular Disorders 2014, 14:14 Page 3 of 10
http://www.biomedcentral.com/1471-2261/14/14angina, stable angina, self-management, self-care, patient
education randomized controlled trials, and clinical trials.
In addition, trial registers including the World Health
Organization (WHO) International Clinical Trial Registry
Platform, clinicaltrial.gov, the ISRCTN register, and
MetaRegister were searched for relevant ongoing or
completed studies with potential publication. We also
conducted hand searches of relevant journals and
secondary references, as well as proceedings of inter-
national conferences; experts were also consulted for
additional sources. No restrictions were applied with
regards to language, sample size or length of follow-up.
Our search strategy was critiqued and replicated by an
information specialist to ensure comprehensiveness.Figure 2 Risk of bias assessment of included trials expressed as perceFinal selection of trials
Five reviewers (MM, JCV, SC, AC, HA) reached consen-
sus on trials to be included in this analysis by reviewing
the titles, abstracts and reports of trials according to the
inclusion criteria specified a priori; individual trial re-
sults were not considered during this process.
Data extraction and appraisal and reporting of
methodological quality
Four reviewers (MM, SOM, SC, NJ) participated in inde-
pendent quality assessment and extraction of process
and outcome data from each new trial according to a
standardized extraction format we have used in other re-
views [22-24]. Methodological quality of included trialsntage.
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of bias assessment [25] including generation of rando-
mization sequence; allocation concealment; blinding of
participants, personnel and outcome assessors (detec-
tion bias); standardized intervention delivery and pres-
ence of co-intervention (performance bias); reliability
and validity of measurement instruments (insensitive
measurement bias); response rate (RR) and attrition
(attrition bias); and selective reporting (reporting bias).
Propensity for selection bias was also assessed. Reported
outcome data were taken directly from included published
trial reports. The report on the quality of methods pre-
sented in this paper is compliant with standards set forth
in the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [26].
Data synthesis and analysis
All outcomes examined were continuous in nature. For
all relevant outcome data, standardized mean differences
(SMD) and 95% confidence intervals were calculated
using RevMan 5.1.7® software [27]. SMDs were deter-
mined using differences in change over baseline post-
intervention across treatment groups, divided by the
pooled standard deviation. If change over baseline was
unavailable, differences in mean values at the end of
the treatment period were used. If some of the required
data were unavailable we used approximations based on
graphic output. For studies reporting only means and
interquartile ranges, means and standard deviations were
estimated [28,29]. A SMD of 0.20 standard deviation
units was considered a small difference between treat-
ment and control groups, a SMD of 0.50 a moderateFigure 3 Comparison of SM versus usual care, outcome angina frequdifference, and 0.80 a large difference [30]. We used
standard inverse-variance, random-effects meta-analysis
to combine the trials.31 Heterogeneity between trials
was evaluated using chi-square tests for the tau-squared
statistic, quantified using the I2 statistic [31], which
describes the percentage of variation across trials attrib-
utable to heterogeneity rather than chance. I2 values of
25%, 50%, and 75% may be considered as indicators of
low, moderate, and high heterogeneity [32], although
this has been shown to depend on the size and number
of trials included [33]. Where significant heterogeneity
was found, we conducted sensitivity analyses removing
studies, such as those with estimated mean values or
those of lower methodological quality, to determine fac-
tors related to the heterogeneity and the effect on the
pooled outcome.
Description of studies
Nine trials [13-21], conducted in 7 countries and pub-
lished between 1994 and 2012 met the criteria for inclu-
sion in this review. Sample sizes ranged from 29 [13] to
452 [17]. Eight of the included trials reported use of an
isolated SM intervention with components designed to
enhance patients’ perceived confidence and skills to
manage symptoms [13-17,19-21]. Control groups re-
ceived usual medical and/or nursing care as described;
no controls were exposed to the intervention during the
study period.
Five trials [13,14,16,17,19] tested small-group interven-
tions (6–15 patients) employing varying combinations of
educational materials, planned exercise, and cognitive-
behavioural techniques targeted at lifestyle and symptomency.
Figure 4 Comparison of SM versus usual care, outcome SL nitrate use.
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or enhancement of physical activity. Intervention duration,
format, and process varied. Four trials tested interventions
with content similar to the group-based interventions but
on an individual basis [15,18,20,21]. All trials included base-
line assessment of participant characteristics and outcomes
prior to randomization. Most trials used symptom diaries
to measure angina symptom profile and related SL nitrate
use; objective measures of ischemia were less often used.
Subjective measures were also most often used to examine
HRQL outcomes and aspects of psychological well-being.
The maximum length of follow up for data pertinent to this
review (i.e., pertinent to the outcomes we examined per se)
was 24 weeks following baseline [15,20,21].
Risk of bias in included studies
Details of our risk of bias assessment are provided in
Figures 1 and 2. The methodological quality of the nine
trials ranged from low [13,14,16-18] to high [15,19-21].
Six of the 9 trials (67%), adequately described the ran-
domization process with respect to sequence generation
and 4 trials clearly reported allocation concealment proce-
dures (44%). Blinding of healthcare personnel caring for
participants (not directly involved in the trials) occurred
in 4 (44%) of the 9 included trials; no trial blinded partici-
pants given that SM interventions are socially-based.
Blinding of outcome assessors was clearly outlined in 5
trials (56%) and incomplete data were addressed in 4
trials (44%). Seven trials (78%) reported on all pre-specified
outcomes at all follow up time points and were free of se-
lective reporting bias. Loss to follow up rates ranged from
0% - 19%. The results of two trials were applicable to men
only [16,17], thereby limiting generalizability.Figure 5 Comparison of SM versus usual care, outcome angina stabilResults
Nine trials, involving 1282 CSA patients in total, were
included. It was not possible to include results from two
trials [17,18] in any pooled estimates of effect due to the
heterogeneity of their respective measures and analyses.
All results pertain to pooled short-term effects, given
the maximum length of follow-up of 24 weeks.
Angina symptom profile
Angina symptom profile was examined with respect to an-
gina frequency and related SL nitrate use, and angina sta-
bility. Three trials [13,15,16] reported on angina frequency
expressed solely as counts of angina attacks in the previ-
ous week while 4 trials [15,19-21] reported changes in
angina frequency via the Seattle Angina Questionnaire
(SAQ) angina frequency subscale (with our without the
additional use of symptom diaries). Therefore, we per-
formed subgroup meta-analyses, separating the studies ac-
cording to form of outcome assessment. In studies where
both data collection methods were used, preference was
given to data gleaned by the SAQ due its well-established
psychometric properties [34]. We then pooled for overall
effect.
Following SM training, there was a significant im-
provement in angina frequency across studies, SMD:
0.30 (95% confidence interval [CI] 0.14, 0.47. p = 0.0003)
(Figure 3). This significant finding was also seen when
trials were grouped by form of outcome assessment,
although the effect size was significantly larger across
trials measuring counts of angina episodes per week,
chi-square (χ2): 5.11 (p = 0.02) (Figure 3). There was
no significant heterogeneity of variances in the overall
pooled analysis or in either subgroup.ity (AS).
Figure 6 Comparison of SM versus usual care, outcome physical limitation (PL).
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interventions resulted in a significant reduction of SL ni-
trate usage, SMD: -0.45 (95% CI −0.77, −0.20. p < 0.001)
(Figure 4). No significant heterogeneity was found.
Three trials [15,19,21] reported on angina stability using
the stability subscale of the SAQ. No significant differ-
ences in angina stability scores were found (Figure 5).
There was mild heterogeneity across studies, I2 = 57%, but
this was not statistically significant.
Health-related quality of life
We examined HRQL outcomes according to the SAQ phys-
ical limitation, disease perception, and treatment satisfaction
subscales [34]. Of the 4 trials reporting SAQ physical limita-
tion scores [15,19-21], one reported post-intervention scores
only while the other 3 reported change from baseline. Use of
SMDs allowed the 4 studies to be pooled (Figure 6). Across
trials, a significant improvement in physical limitation scores
was observed post-intervention, SMD: 0.38 (95% CI 0.20,
0.55. p < 0.0001); statistical heterogeneity was negligible, I2 =
17%. Three [15,19,21] and 4 [15,19-21] trials reported disease
perception and treatment satisfaction scores, respectively
(Figures 7 and 8). No significant improvements in disease
perception or treatment satisfaction were found and there
was no significant heterogeneity of variances across studies
for these outcomes.
Psychological well-being
Data pertaining to psychological well-being [15,20,21]
were amenable to pooling using the Hospital Anxiety
and Depression Scale (HADS) [35]. We initially foundFigure 7 Comparison of SM versus usual care, outcome disease perceno significant difference in anxiety scores (HADS-A),
yet there was considerable heterogeneity across studies,
I2 = 98% (Figure 9). Sensitivity analysis, via removal of the
trial by Furze et al. [20] with the widest CI, improved
heterogeneity (I2 = 0%) and suggested an overall signifi-
cant reduction in HADS-A scores following SM training
(Figure 10), SMD: −0.27 (95% CI −0.47, −0.06. p = 0.01).
With respect to depression (HADS-D), there was a sig-
nificant difference in HADS-D scores following SM train-
ing SMD: −1.38 (95% CI −2.46, −0.30. p = 0.01) (Figure 11).
However, there was considerable heterogeneity across
studies (I2 = 96%) which was statistically significant. Fol-
lowing sensitivity analyses, no removal of a single study
improved heterogeneity such that I2 was <80%. Regard-
less, we observed significant reduction in HADS-D
under all scenarios, suggesting that the positive impact
of SM training on depression is stable.
Discussion
In this review we have appraised and summarized the
results of 9 trials of interventions for angina self-
management, conducted across 7 countries, in a var-
iety of outpatient clinic settings. All trials reviewed
included patients with stable angina, characterized by
CCS class I – IV symptoms. The methodological qual-
ity of the trials ranged from low to high, with 5 trials
blinding outcome assessors and 4 trials blinding health
care personnel directly caring for participants (outside
of direct trial-related activities).
The first outcome examined was angina symptom pro-
file including angina frequency and related SL nitrate use,ption (DP).
Figure 8 Comparison of SM versus usual care, outcome treatment satisfaction (TS).
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expressed as either weekly count of angina episodes or in
the form of standardized scores via the angina frequency
subscale of the SAQ. Consistent with a prior, smaller scale
review [23], we found that SM interventions significantly
improve the frequency of symptoms in the short term and
reduce usage of SL nitrates. We also observed a SMD in
overall angina frequency of .31 (95% CI 0.51, 0.47), sug-
gesting a lesser magnitude of effect on this outcome than
what has been found previously [23]. This difference is
likely due to the fact that our overall pooled estimate in-
cluded trials which employed the SAQ to measure angina
frequency, as opposed to others which employed diaries to
capture counts of weekly angina episodes. In our subgroup
analysis, the effect size for angina frequency was signifi-
cantly larger across trials which reported angina counts
only. Some dilution of the overall pooled effect was
to be expected given that the SAQ angina frequency
subscale [34] captures how many times, on average, one
has had angina over a recall period of 4 weeks, expressed
in terms of ranges (e.g. 1–2 times per week). Therefore,
trials employing this measure are not likely to capture true
angina frequencies, but rather, important changes in
symptom trends [34,36].
More recent trials [19-21] in this review did not evaluate
reductions in SL nitrate usage. This may reflect current
understanding that such reductions are not always clinic-
ally desirable [37,38]. A noted gap in SL nitrate-related
education across a number of SM trials we reviewed was
the omission of education about prophylactic nitrate use,
which can significantly reduce exertional angina [37,38].Figure 9 Comparison of SM versus usual care, outcome anxiety (HADThis gap may be reflective of widespread usage of long-
acting nitrate formulations across clinical settings [37].
The final component in the angina symptom profile
was angina stability. No significant differences in SAQ
angina stability scores were found across the three trials
reporting on this outcome and the observed statistical
heterogeneity across studies was not significant. This find-
ing is likely explained by variable levels of effectiveness
across interventions to optimize participants’ levels of
activity. The angina stability subscale measures changes
in the frequency of angina at patients’ most strenuous
levels of activity [34]. Achievable levels of physical exertion
would have varied widely given the divergence in scope
and format of SM interventions across trials reviewed.
Health-related quality of life outcomes we examined
were according to the SAQ physical limitation, disease
perception, and treatment satisfaction subscales. SM train-
ing yielded significant improvement in angina-induced
physical limitations, but did not improve treatment satis-
faction. The SM interventions across the 4 trials contribut-
ing to the pooled effect on physical limitation [15,19-21]
included the Chronic Angina Self-Management Program
(CASMP) [19] and the Angina Plan [15,20,21]. The effect-
iveness of these interventions to improve physical limita-
tion scores is likely explained by their strong grounding in
self-efficacy theory [12] and supportive approaches to goal
setting which target realistic, incremental improvements
in functional status.
There was no heterogeneity of variances across trials in
treatment satisfaction scores and lack of improvement in
this outcome, across trials as well as our pooled analysis,S-A).
Figure 10 Sensitivity analysis: comparison of SM versus usual care removing the influence of data from Furze et al. [20], outcome
anxiety (HADS-A).
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treatment satisfaction scale [34]. This scale is comprised
of 3 items oriented toward patient satisfaction with phys-
ician care [34]. Interventions of included trials were de-
livered by either nurses [15,19,21] or lay facilitators [20],
not physicians. Moreover, relatively short-term duration
follow up data collection (maximum: 24 weeks) across tri-
als would not have allowed sufficient time for improved
satisfaction with physician-related care in the clinical set-
ting. At the individual level, care delivery by more than
one physician could also have introduced loss of precision
in the measurement of treatment satisfaction.
With respect to disease perception, SM interventions
appeared on the whole, less effective for improving this
outcome. Previously, we did find a positive pooled effect
for disease perception, but CIs were wide signaling cau-
tion in our interpretation of the result. The trial by Zetta
et al. (n = 233) [21] carried 48.8% of the weight within
this current analysis and their SM intervention had no
significant impact on disease perception scores. The lim-
ited ability of SM training to improve these scores to
date may be a function of heavy disease-related burden
among angina sufferers; it may also be an artifact of
short-term follow up across studies, given that meaning-
ful changes in perceived disease status can take time. In
this case, measurement is not likely the issue. The SAQ
disease perception subscale is well-established as sensi-
tive to change and is also highly correlated with generic
self-report measures of general health and vitality [36].Figure 11 Comparison of SM versus usual care, outcome depressionThe final outcome of this review was psychological
well-being. The 3 trials included in our analysis [15,20,21]
reported on anxiety and depression using the HADS [35].
We found the positive, significant impact of SM training
on depression (HADS-D) to be stable, despite our inability
to reduce statistical heterogeneity below I2 = 80% via sen-
sitivity analyses. This finding is encouraging given that
depression is predictive of a number of poor cardiac-
related outcomes [39]. Each of the trials contributing to
our pooled HADS estimates employed the Angina Plan
[15,20,21]. The positive result speaks to the importance of
the design of this intervention with respect to the inclu-
sion of individualized attention and supportive counseling.
The impact of group-based SM [19] on HADS-D has not
been examined in primary trials.
Unlike depression, the impact of SM training on anxiety
is less certain. Initially, we found no significant results.
Once we removed the trial with the widest CI [20] our
sensitivity analysis demonstrated a significant yet small
overall reduction in HADS-A scores, SMD −0.27. Inter-
vention structure and process were homogenous among
included trials and therefore cannot explain our result.
Given the heterogeneity observed in HADS scores, a sin-
gle trial, regardless of size, is unlikely to confirm a signifi-
cant pooled effect of SM training on anxiety; we estimate
that approximately 6 or more trials, with a total sample
size of 100 or more, would be required to establish a sig-
nificant intervention effect with 80% conditional power
(assuming a small effect size as observed in this sensitivity(HADS-D).
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contributed to an overall lack of measurement precision.
Future trials should therefore employ a cardiac-specific
measure of anxiety to make more definitive conclusions
about the ability of SM to impact anxiety positively.
Study limitations, summary and implications
As Le Lorier et al. [40] have argued about sources of bias in
meta-analyses, an important limitation of this review is that
our conclusions may be subject to the same potential for bias
as the smallest trials included [13,16]. Yet, threats to validity
are likely offset by our rigorous approach to risk of bias assess-
ment as well as formal evaluation of the impact of statistical
heterogeneity on outcomes. Our results for psychological out-
comes must be interpreted with caution due to heterogeneity.
The methodological quality of the included trials also ranged
from low to high. While it is not possible to blind participants
in socially-based interventions, blinding of outcome assessors
was addressed in just 5 of the 9 trials examined.
Conclusions
In summary, SM interventions appear to be effective for
improving the frequency of angina symptoms and re-
lated physical limitation. SM training also appears to
have an overall positive impact on depression scores,
which has not been found previously [22,23]. Interven-
tions in this review were delivered in either group-based
or individual-based formats; intervention duration and
intervener credentials also varied. The ideal intervention
design to yield maximal and replicable long-term benefit
for patients remains unknown. Future work is needed to
examine the relative effectiveness of successful interven-
tion designs in the context of robust, multi-site trials
with long-term follow up. Clarity is also needed regard-
ing the ability of SM interventions to reduce cardiac-
specific anxiety for people living with CSA.
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